Informe Analisis Amilasa en Sangre
Transcript of Informe Analisis Amilasa en Sangre
-
8/16/2019 Informe Analisis Amilasa en Sangre
1/32
2016 - I
DOSAJE DE AMILASA SÉRICA Y
URINARIA
-
8/16/2019 Informe Analisis Amilasa en Sangre
2/32
UNIVERSIDAD PRIVADA SAN JUAN BAUTISTA
FACULTAD DE CIENCIAS DE LA SALUD
ESCUELA PROFESIONAL DE MEDICINA HUMANA
INFORME DE INVESTIGACIÓN
DOSAJE DE AMILASA SÉRICA Y URINARIA
ELABORADO POR:
DONAYRE ARAUJO CLAUDIA SUSANA
-
8/16/2019 Informe Analisis Amilasa en Sangre
3/32
ICA – PERÚ
2016
INTRODUCCIÓN
La a!"a#a$ %&'(!'a%a )a*!+' ,)!a"!'a$ -'a &'.!a /!%("a#a -& )!&'& "a -'3!4'
%& 3a)a"!.a "a &a33!4' %& /!%4"!#!# %& "(# &'"a3 15 %&" 3(,('&')& 75a!"a#a a"
%!8&! &" 8"-348&'( 9 &" a"!%4' ,aa (a a.3a #!," S& ,(%-3&
,!'3!,a"&')& &' "a# 8"a!"a#&!a?;
F-& "a ,!&a &'.!a &' #& !%&')!!3a%a 9 a!#"a%a ,( A'#&"& Pa9&' &' 1$ -!&'
&' -' ,!'3!,!( "a *a-)!.4 3(' &" '(*& %& %!a#)a#a;
A!"a#a ,a'3&
-
8/16/2019 Informe Analisis Amilasa en Sangre
4/32
E,"!3a "(# -")a%(# (*)&'!%(# 3(' "(# =a"( '(a" %& &&&'3!a %&
"a )+3'!3a ,aa ,(%& #-8&! -'a ,(#!*!"!%a% %!a8'(#)!3a;
II. MARCO TEORICOPancreatitis agudaLa ,a'3&a)!)!# a8-%a$ ( !'"aa3!4' a8-%a %&" ,?
-
8/16/2019 Informe Analisis Amilasa en Sangre
5/32
• (i)ersensi"i!idad + rigide, #uscu!ar en e! a"d#en$ ruids -idrares
dis#inuids ausentes;
• Signs )u!#nares: )&)( *a#a"$ a)&"&3)a#!a 9 %&a& ,"&-a" )&
")!(
-
8/16/2019 Informe Analisis Amilasa en Sangre
6/32
3("&33!4' "-!%a %& 8a' )aaK( ,-&%& &)&!(!.a#& )&,a'a&')& ,(
-'a a#a ,a",a*"&;
LABORATORIO
EN1IMAS PANCREATICAS2
La #&'#!*!"!%a% %& "a# &'.!a# ,a'3&
-
8/16/2019 Informe Analisis Amilasa en Sangre
7/32
8"
-
8/16/2019 Informe Analisis Amilasa en Sangre
8/32
EN*ERMEDADE
S
PANCREATICAS
TRANSTORNOS
NO
PANCREATICOS
OTROS
TRANSTORNOS
ABDOMINALES Pa'3&a)!)!#
34'!3a
Ta-a)!#(
,a'3&
-
8/16/2019 Informe Analisis Amilasa en Sangre
9/32
&*a8( a3(,aKa a "a a!"a#a &' "(# a"#(# ,(#!)!=(# #&3-'%a!(# a
,a)("(8a *!"!a a8-%a$ "3&a ,&(a%a$ (*#)-33!4' !'))!'a"$ )(*(#!#
&')+!3a 9 a,&'%!3!)!# a8-%a; La a3)!=!%a% %& "a "!,a#a #+!3a a-&')a %&(a ,aa"&"a a "a %& "a a!"a#a$ 9 "a %&)&!'a3!4' %& a*a# &'.!a#
a-&')a &" &'%!!&')( %!a8'4#)!3(;
• L(# '!=&" %& "!,a#a ,-&%&' ,&a'&3& &"&=a%(# %& @ a 1 %a#; La "!,a#a
,-&%& #& a/(a "a &'.!a a# !'%!3a%a ,aa )a*"&3& -' %!a8'4#)!3( %&
,a'3&a)!)!# a8-%a; L(# a=a'3 &' "(# #-#)a)(# 9 "a )&3'("(8a (&3&' a"
&%!3( &( (,3!('$ ,&3!a"&')& 3-a'%( #& &3-& a -' a'
-
8/16/2019 Informe Analisis Amilasa en Sangre
10/32
&"&=a%a %& @ a 1 %a#; C(' ,&3)( a )a ,-&*a a"8-'(# a-)( a%=!&)&' -&
'( #-&"&' #& !a*" 3-a'%( /a9 -' a-&')( '!( ( (%&a%( %& "a a!"a#a
)()a" &' )(# 3a#(# -")a )!" &3-! a -' a'
-
8/16/2019 Informe Analisis Amilasa en Sangre
11/32
• (i)erg!uce#ia2 S&3-'%a!a a ")!," a3)($ &')& &""(# "a &'( ,(%-33!4'
%& !'#-"!'a$ &" a-&')( &' "a "!*&a3!4' %& 8"-3a84' 9 "a a9( ,(%-33!4' %&
8"-3(3()!3(!% 9 %& 3a)&3("a!'a# #-,a&'a"
• Par0#etrs de C!estasis 5BILIRRIBINA$ *AL$
4AMA4LUTAMILTRANSPEPTIDASA 6 TRANSAMINASAS72 La &"&=a3!4' %&
)(# ,a
-
8/16/2019 Informe Analisis Amilasa en Sangre
12/32
,a'3&a)!)!# a8-%a$ &' &" %!a8'(#)!3( &)!("48!3( &%!a')& "a &=a"-a3!4' %& "a
=3-"a 9 "a =a *!"!a; E' 3-a')( a" %!a8'4#)!3( &3(8
-
8/16/2019 Informe Analisis Amilasa en Sangre
13/32
La &a"!.a3!4' %& -'a TC a') %& "a# /#; %& &=("-3!4' %%& &" !'!3!( %& "a
&'&&%a%$ )!&'%& a !'a=a"(a "a 8a=&%a% %&" 3-a%( "(3a" %& ,a'3&a)!)!# 9
,( )a')($ &" (&')( !%4'&( %& #- &a"!.a3!4' &')& "a# 9 @2 /#;
D!a8'4#)!3(
E' &" 3-#( %& "a ,a'3&a)!)!# a8-%a #& )!&'&' -& ,"a')&a %(# )!,(# %&
%!a8'4#)!3(#:
1; D& E'&&%a%
2; D& S&=&!%a% ( Ga=&%a%
E" %!a8'4#)!3( %& &'&&%a% #& ,"a')&a &' *a#& a "a# #!8-!&') ,-&*a#$ ,(
,(#&& "(#
-
8/16/2019 Informe Analisis Amilasa en Sangre
14/32
-
8/16/2019 Informe Analisis Amilasa en Sangre
15/32
3(,"!3a3!(' 9 ()a"!%a% &' &" ,a3!&')& 3(' ,a'3&a)!)!# a8-%a; E"
%a(""( %& )& 3('3&,)( '( #4"( /a %&(#)a%( #- !,()a'3!a &' &"
a'&( a3!('a" %&" ,a3!&')& ,&3!3($ #!'( )a*!+' &' "a &=a"-a3!4' %&'-&=a# (%a"!%a% )&a,+-)!3a#; A "( "a8( %& "a# ")!a# %(# %+3a%a# #& /a'
,"a')&a%( %!&&') (%&"(# ,aa )a*"&3& ,('4#)!3($ /a*!&'%( #!%(
Ra'#(' 9 &" 8-,( %& Ba' 9 Q!#& "(# ,!&(# &' %a(""a )a (%a"!%a%
%!a8'4#)!3a;
:. Mde! de Ransn.
S& *a#a &' %&)&!'a 11 ,a. Mde! de Ban/ + ise.
E#)& #!#)&a !'3"-9& ,a
-
8/16/2019 Informe Analisis Amilasa en Sangre
16/32
a8-%a$ 9a -& #- ,(#!)!=!%a% &-!=a"!4 a "a 3(,('%!&')& a
-
8/16/2019 Informe Analisis Amilasa en Sangre
17/32
,()&'a# 9 ,( ")!( "a "!,a#a a "a %& "a# 8a#a#; La -'3!4' &'%(3!'a %&"
,!#"() %& La'8&/a'#? 9
)a# #& &'3a8a' %& ,(%-3! !'#-"!'a ,aa &)a*("!.a "a 8"-3(#a; P(%&(#=!=! #!' ,3a#! &" 0 %& "(# ,a3!&')? 9 #& 3&& -& "a !'8)a 3(')!'-a%a%& 0 8 %& a"3(/(" %!a!(# &' &" /(*& 9 60 8 &' "a -&$ #&a' %(#!#
#-!3!&') ,aa %a(""a"a; N( )(%a# "a# ,&#('a# 3(' )a !'8)a %&
a"3(/(" %a(""a' -'a ,a'3&a)!)!# 34'!3a; P&'#a(# -& ,(*a*"&&')&
)!&'&' -& &!#)! ()(# a3)( a3!"!)a%($ 3(( ,( &&,"( ,a&3& #& /(9
&' %a &" 3a#( %&" )a*a3(;
E' a,(!a%a&')& -' 20 %& "(# 3a#(# '( &'3(')a(# -'a 3a-#a
-&%a'%( 3a)a"(8a%a "a ,a'3&a)!)!# 3(( !%!(,
-
8/16/2019 Informe Analisis Amilasa en Sangre
18/32
&')& "a )&3&a 9 3-a)a %+3a%a %& "a =!%a &' "(# ,a3!&') a"3(/4"!3(# 9 ,-&%&
%a,a&3& ,(')
-
8/16/2019 Informe Analisis Amilasa en Sangre
19/32
&-!&&' &'%(#3(,!a?; S! #& )a)a %& =!#-a"!.a &( &" )&!%( ,a'3&&3(5&'%(#3(,!a? 3(' )(a %& -)a,aa )-%!( %&" )&!%(; E#)a &,"(a3!4' '!a&')& !'=a#!=a 9 ,&3!#a %&
"a !')(%-33!4' %& -' &'%(#3(,!( /a#)a &" %-(%&'(; La 3("a'8!(,a'3&a)(8aa
&)48a%a &'%(#34,!3a >CPRE? #& &=a< ,aa "(# ,a3!&') &' "(# -& #&
)&'8a -& &a"!.a -'a a'!(*a )&a,+-)!3a; E" %!a8'4#)!3( %a "a !'#-!3!&'3!a
,a'3&
-
8/16/2019 Informe Analisis Amilasa en Sangre
20/32
Amilasa en sangre -'a &'.!a -& a9-%a a %!8&! "(# 3a*(/!%a)(# 9 #&
,(%-3& &' &" ,
-
8/16/2019 Informe Analisis Amilasa en Sangre
21/32
L( -& #& #!&')& %-a')& &" a'3(( ,a,&a#? ( -'a (*#)-33!4'
https://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000221.htmlhttps://www.clinicadam.com/salud/5/000272.htmlhttps://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000236.htmlhttps://www.clinicadam.com/salud/5/000264.htmlhttps://www.clinicadam.com/salud/5/001138.htmlhttps://www.clinicadam.com/salud/5/001557.htmlhttps://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000221.htmlhttps://www.clinicadam.com/salud/5/000272.htmlhttps://www.clinicadam.com/salud/5/000287.htmlhttps://www.clinicadam.com/salud/5/000236.htmlhttps://www.clinicadam.com/salud/5/000264.htmlhttps://www.clinicadam.com/salud/5/001138.htmlhttps://www.clinicadam.com/salud/5/001557.html
-
8/16/2019 Informe Analisis Amilasa en Sangre
22/32
• O3"-#!4' !'))!'a"
• Ma3(a!"a#&!a
• O*#)-33!4' %& "a# =a# *!"!a ( ,a'3&a3--"a3!4' %& #a'8& %&*a( %& "a ,!&"?;
• I'&33!4' >-' !( "&=& 3a%a =&. -& #& ,&')a -,)-a %& "a ,!&"?;
A#i!asa en rina
Amilasa en orina -' a'
-
8/16/2019 Informe Analisis Amilasa en Sangre
23/32
La a!"a#a )a*!+' #& ,-&%& &%! 3(' -' a' A#,!!'a?• P"%(a# a')!3('3&,)!=a#• F
-
8/16/2019 Informe Analisis Amilasa en Sangre
24/32
• E*aa.( )-*
-
8/16/2019 Informe Analisis Amilasa en Sangre
25/32
M&.3"a(# ,( a8!)a3!4' #-a=&; R&)!a(# "(# )-*(# %&" *aK( 9 a8&8a:
A8-a %)!"a%a " "
M&.3"a(# ,( !'=&#!4';F!'a"&')&$ "&&(# &' ,&3)(()4&)( a 0 '$ ""&=a'%( a 3&( &" a,aa)(
3(' a8-a %)!"a%a;L&&(# =&3 3(' !')&=a"( %& -' !'-)( A*# 0 A*# 1 A*# 2 A*# A*#
V. RESULTADOS2
a*#(*a'3!a# 2
V' #-&( ,"a#a W 0 -"
Pr 8r#u!a -a!!are#s !s resu!tads
A#i!asa UA3d! ; A"s. Cntr! A"s. Muestra < :
A"s. Cntr!
A*#;0 0;6
0;0
A*#;1 0;00
0;01
A*#;2 0;1 0;12 0;00@ 2 .K
0;02@
A*#; 0;
0;00
A*#; 0;
-
8/16/2019 Informe Analisis Amilasa en Sangre
26/32
VI. CUESTIONARIO2
:. E-' ,("!,+,)!%( %& a!'(
-
8/16/2019 Informe Analisis Amilasa en Sangre
27/32
#&3&)a#& &' "a -3(#a %&" !'))!'( %&"8a%( 3-a'%( &" ,H %&" 3(')&'!%(
%-(%&'a" %!&'%& ,( %&*a( %& $ ( 9 #- "!*&a3!4' a-&')a -3/(
3-a'%( &" ,H 3a& a ;E""( /a3& -& &" ,. En una )ancreatitis 'u i#)rtancia tiene e! dsae de !as en,i#as2
!i)asa$ tri)sina$ e!astasa + 8s8!i)asa A>GA#i!asa tta!• La 3('3&')a3!4' #+!3a %& a!"a#a #& -#a %& (a 8&'&a"!.a%a 3((
,-&*a %& %&)&33!4' #!#)&
-
8/16/2019 Informe Analisis Amilasa en Sangre
28/32
%& )a &'.!a; L(# =a"( %& "a a!"a#a &' #-&( #(' %& -)!"!%a% #("(
,aa &" %!a8'4#)!3($ '( 8-a%a' 3(&"a3!4' 3(' "a #&=&!%a% %&" 3-a%($
,( "( )a')( '( )!&'&' =a"( ,('4#)!3(;>5@?
• S- #&'#!*!"!%a% %&" $ #- ,&3!!3!%a% %&" 9 #- =a"(
,&%!3)!=( ,(#!)!=( %&" 6;La# #!8-!&') #(' #!)-a3!(' -& ,-&%&' 8&'&a a"#(# '&8a)!=(#:a? S! #& &)a#a >%& 2 a %a#? "a (*)&'3!4' %& "a -)a %& #a'8&;*? S! &" )a#)('( #-*9a3&')& -'a ,a'3&a)!)!# 34'!3a &' =&. %& -'a
,a'3&a)!)!# a8-%a;3? P&'3!a %& /!,&)!8"!3&!%&!a;Li)asaE# "a #&8-'%a %&)&!'a3!4'
-
8/16/2019 Informe Analisis Amilasa en Sangre
29/32
• Ha9 -& )&'& &' 3-&')a -& "a %&)&!'a3!4' %& "a !#(a!"a#a '(
,&!)& %!&&'3!a "a# 3a-#a# !'))!'a" %& /!,&a!"a#&!a; E#)( #&
%&*& a "a a-#&'3!a %& "a !#(a!"a#a S ,( %&*a( %&" A'8-"( %& )&!).$ %&a'&a -& 3-a"-!& /!,&a!"a#&!a %& (!8&' !'))!'a" #& %&*&
(.(#a&')& a -'a &"&=a3!4' a!#"a%a %& "a !#(a!"a#a P;• E' &" #-&( '(a" &" a" %& "a a!"a#a %& (!8&' ,a'3&
-
8/16/2019 Informe Analisis Amilasa en Sangre
30/32
15 E' "a BOCA &%!a')& "a I'#a"!=a3!4'$ "a #a"!=a 3(')!&'& -'a 1 &'.!a
%!8)!=a ""aa%a P)!a"!'a ( A!"a#a #a"!=a" -& 3(!&'.a 3(' "a %&8a%a3!4'
,!a!a %&" A"!%4' &' a")(#a >D!#a3P("!#a3PAL? %&
-
8/16/2019 Informe Analisis Amilasa en Sangre
31/32
>a!"a#-!a?;E#)a &'.!a -9 #&'#!*"& ,&( -9 !',&3!3a 9a -& /a#)a 1 %&
,a3!&') 3(' a*%(&' a8-%( ,&')a' -'a &"&=a3!4' %& "a !#a &'
a-#&'3!a %& -'a ,a'3&a)!)!# a8-%a >a"#(# ,(#!)!=(#?;E#)a '( )!&'& =a"( &' &" ,('4#)!3( %& "a PA 9 '( %&*& #& #("!3!)a%a "-&8(
%& )a*"&3!%( &" %!a8'(#)!3($ &3&,)( 3-a'%( #& #(#,&3/& %& -'a &3!%!=a
%& "a &'&&%a%;E# !,()a')& #&Ka"a -& &!#)&' ()a# &'&&%a% -& ,(%a' #!-"a
-'a PA )&'!&'%( #!&,& -& %a)a -'a 3("&3!#)!)!# a8-%a$ (*#)-33!4'
!'))!'a" ( ,&(a3!4' %& =!#&a /-&3a a') %& &)!-&)a a -' ,a3!&')& 3('
PA 9a -& )(# #(' 3-a%( -!8!3(# %& &&8&'3!a a %!&&'3!a %& "a PA;E" ,(*"&a '( %!a8'4#)!3( &' "a ,a'3&a)!)!# a8-%a$ '! #- 3('!a3!4'$
'! #- &)!("(8a$ "( 3(,"!3a%( "a !%&')!!3a3!4' 9 )a)!!3a3!4' 3("a'8!(,a'3&a)(8aa &)48a%a &'%(#34,!3a? 5 ,-&*a -&
-)!"!.a -' )-*( "&!*"& !')(%-3!%( ,( "a *(3a /a3!a &" a8( 9 &"
)4a8($ a"3a'.a'%( &" ,
-
8/16/2019 Informe Analisis Amilasa en Sangre
32/32
(3a#!(' &)!a$ 3